ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1009-1013

  You, Liang ^a   Yang, Cheng Ta ^a   Jablons, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; PROTEIN P53; VIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; DRUG POTENTIATION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOPATHOGENIC EFFECT, VIRAL; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034652615     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Minna, J. D. Neoplasm of the lung. In: A. S. Fauci, E. Braunwald, K J. Isselbacher, and J. B. Martin (eds.), Harrison's Principles of Internal Medicine, Ed. 14, pp. 522-562. New York: McGraw-Hill, 1998.
2. Sekido, Y., Fong, K. M., and Minna, J. D. Progress in understanding the molecular pathogencsis of human lung cancer. Biochim. Biophys. Acta. I378: F21-F59, 1998.
3. Carbone. D. P. The biology of lung cancer. Semin. Oncol., 24: 388-401, 1997.
4. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC). 253: 49-53, 1991.
5. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond.), 49: 4682-4689, 1990.
6. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms [see comments]. Science (Washington DC), 250: 1233-1238, 1990.
7. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp. B. L., Carrasco, C. H., Person, D. Z., Hong, W. K., Komaki, R., Lee. J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh. G. L. Dolormente, M. M., Han, C. I., Martin. F. D., Yen. N., Xu. K., Stephens, L. C., McDonnell. T. J., Mukhopadhyay. T., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer [see comments], Nat. Med., 2. 985-991, 1996.
8. Roth, J. A., Swisher, S. G., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., El-Naggar, A. K., Fossella, F. V., Glisson, B. S., Hong, W. K., Khurl. F. R., Kurie, J. M., Nesbitl, J. C., Pisters, K., Putnam, B., Schrump, D. S., Shin. D. M., and Walsh, G. L. Gene therapy for non-small cell lun J.g cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25: 33-37, 1998.
9. Bischoff, J. R., Kim, D. H., Williams, A., Heise, C . Horn, S., Muna, M., Ng, L., Nye, J A., Sampson-Johannes, A., Fattacy, A., and MeCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science (Washington DC), 274: 373-376, 1996.
10. Heise, C., Sampson-Johannes, A., Williams, A., MeCormick, F., Von Hoff, D. D., and Kim, D. H. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat. Med., 3: 639-645, 1997.
11. Kim, D., Hermiston, T., and MeCormick, F. ONYX-015: clinical data are encouraging. Nat. Med., 4: 1341-1342, 1998.
12. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nat. Med., 4: 1068-1072, 1998.
13. Shu, S. Y., and Rosenberg, S. A. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res., 45: 1657-1662, 1985.
14. Kressner, U., Inganas, M., Byding. S., Blikstad, I., Pahlman, L., Glimelius, B., and Lindmark, G. Prognostic value of p53 genetic changes in colorectal cancer. J. Clin. Oncol., 17: 593-599, 1999.
15. Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T. D., Field, J. K., and Kittas, C. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am. J. Pathol., 153: 1749-1765, 1998.
16. Vonlanthen, S., Heighway, J., Tschan. M. P., Borner, M. M., Altermatt, H. J., Kappeler. A., Tobler. A., Fey. M. F., Thatcher. N., Yarbrough, W. G., and Betticher, D. C. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 over-expression. Oncogens, 17: 2779-2785, 1998.
17. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters. G., Ludwig, R. L., and Vousden, K. H. p14ARF links the tumour suppressors RB and p53. Nature (Lond.), 395: 124-125, 1998.
18. Zhang, Y., Xiong. Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
19. Rothmann, T., Hengstermann, A., Whitaker, N J., Scheffner, M., and zur Hausen, H. Replication of ONYX-015. a potential anticancer adenovirus. is independent of p53 status in tumor cells. J Virol., 72: 9470-9478, 1998.
20. Goodrum, F. D., and Omelles, D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol., 72: 9479-9490, 1998.
21. Tianen, M., Spitkovsky, D., Jansen-Durr, P., Sacchi, A., and Crescenzi, M. Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms. Mol. Cell. Biol., 16: 5302-5312, 1996.
22. Sanchez-Prieto, R., Quintanilla, M., Cano, A., Leonart, M. L., Martin, P., Anaya. A., and Ramon y Cajal, S. Carcinoma cell lines become sensitive to DNA-damaging agents hy the expression of the adenovirus E1A gene. Oncogene, 13: 1083-1092, 1996.
23. MeCormick, F. Cancer therapy based on p53. Cancer J. Sci. Am., 5: 139-144, 1999,
24. Scheffner, M., Munger, K., Byrne, J. C. and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
25. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan. S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend. S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drag screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
26. Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., McClintock, P. R., Linnoila, R. I., Matthews, M. J., Bunn, P. A., Jr., Carney, D., Minna, J. D., and Mulshine, J. L NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. Suppl., 24: 32-91, 1996.